×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CMRX – chimerix, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CMRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/11
08:21 am
cmrx
Chimerix, Inc. (NASDAQ: CMRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
High
Report
Chimerix, Inc. (NASDAQ: CMRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
12/10
06:20 pm
cmrx
Chimerix, Inc. (NASDAQ: CMRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
Low
Report
Chimerix, Inc. (NASDAQ: CMRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
12/10
09:46 am
cmrx
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday? [Yahoo! Finance]
Medium
Report
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday? [Yahoo! Finance]
12/9
04:19 pm
cmrx
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End [Yahoo! Finance]
High
Report
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End [Yahoo! Finance]
12/9
04:01 pm
cmrx
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
High
Report
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
12/6
04:01 pm
cmrx
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/18
11:34 am
cmrx
Chimerix, Inc. (NASDAQ: CMRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
Low
Report
Chimerix, Inc. (NASDAQ: CMRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
11/11
11:18 am
cmrx
Chimerix, Inc. (NASDAQ: CMRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Low
Report
Chimerix, Inc. (NASDAQ: CMRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/10
08:50 am
cmrx
Form 8-K CHIMERIX INC For: Dec 09
High
Report
Form 8-K CHIMERIX INC For: Dec 09
11/14
04:21 pm
cmrx
Form 8-K CHIMERIX INC For: Nov 12
Medium
Report
Form 8-K CHIMERIX INC For: Nov 12
11/7
07:29 am
cmrx
Form 10-Q CHIMERIX INC For: Sep 30
Medium
Report
Form 10-Q CHIMERIX INC For: Sep 30
11/7
07:11 am
cmrx
Form 8-K CHIMERIX INC For: Nov 07
Medium
Report
Form 8-K CHIMERIX INC For: Nov 07
10/30
08:01 pm
cmrx
Form 4 CHIMERIX INC For: Oct 28 Filed by: MIDDLETON FRED A
Low
Report
Form 4 CHIMERIX INC For: Oct 28 Filed by: MIDDLETON FRED A
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/28
Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
37.8%
2/25 Q4/2019 12/31/2019 EPS -0.060 ZacksConsensus -0.170 ActVsEst 0.110 - Beat 15.6%
3/24 Form 8-K CHIMERIX INC For: Mar 18 12.3%
12/10 Form SC 13G/A CHIMERIX INC Filed by: ArrowMark Colorado Holdings LLC 10.7%
5/9 Chimerix's (CMRX) CEO Mark Iwicki on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 8.7%
11/4 Chimerix to Present at Upcoming Investor Conferences 8.2%
5/13 Form 4 CHIMERIX INC For: May 10 Filed by: MIDDLETON FRED A 7.6%
1/7 Chimerix Inc (NASDAQ: CMRX) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 7.4%
5/10 Chimerix Inc (NASDAQ: CMRX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 5.4%
2/14 Form SC 13G/A CHIMERIX INC Filed by: Redmile Group, LLC 5.4%
2/25 Q4/2019 12/31/2019 EPS -0.060 ZacksConsensus -0.170 ActVsEst 0.110 - Beat 15.6%
3/24 Form 8-K CHIMERIX INC For: Mar 18 12.3%
12/10 Form SC 13G/A CHIMERIX INC Filed by: ArrowMark Colorado Holdings LLC 10.7%
5/9 Chimerix's (CMRX) CEO Mark Iwicki on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 8.7%
11/4 Chimerix to Present at Upcoming Investor Conferences 8.2%
5/13 Form 4 CHIMERIX INC For: May 10 Filed by: MIDDLETON FRED A 7.6%
1/7 Chimerix Inc (NASDAQ: CMRX) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 7.4%
5/10 Chimerix Inc (NASDAQ: CMRX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 5.4%
2/14 Form SC 13G/A CHIMERIX INC Filed by: Redmile Group, LLC 5.4%
TOP News Decliners
12/10
Chimerix Presents Updated Results from Phase 2 Clinical Trial of DSTAT in Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia at American Society of Hematology Annual Meeting
-26.0%
9/30 Chimerix Announces Exclusive Global License Agreement with SymBio Pharmaceuticals for Brincidofovir -12.5%
1/29 Chimerix Presents Data Supporting Brincidofovir as a Potential Treatment for Smallpox at 2020 American Society for Microbiology Biothreats Meeting -9.3%
2/25 Form 3 CHIMERIX INC For: Feb 21 Filed by: Multani Pratik S -7.0%
2/24 Form 8-K CHIMERIX INC For: Feb 21 -4.9%
8/1 Chimerix Inc (NASDAQ: CMRX) had its price target raised by analysts at HC Wainwright from $5.00 to $7.00. They now have a "buy" rating on the stock. -4.6%
9/2 Chimerix Inc (NASDAQ: CMRX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -4.5%
1/23 Form 4 CHIMERIX INC For: Jan 21 Filed by: Jakeman David -4.0%
10/3 Form 8-K CHIMERIX INC For: Sep 30 -4.0%
7/31 Form D CHIMERIX INC -3.9%
9/30 Chimerix Announces Exclusive Global License Agreement with SymBio Pharmaceuticals for Brincidofovir -12.5%
1/29 Chimerix Presents Data Supporting Brincidofovir as a Potential Treatment for Smallpox at 2020 American Society for Microbiology Biothreats Meeting -9.3%
2/25 Form 3 CHIMERIX INC For: Feb 21 Filed by: Multani Pratik S -7.0%
2/24 Form 8-K CHIMERIX INC For: Feb 21 -4.9%
8/1 Chimerix Inc (NASDAQ: CMRX) had its price target raised by analysts at HC Wainwright from $5.00 to $7.00. They now have a "buy" rating on the stock. -4.6%
9/2 Chimerix Inc (NASDAQ: CMRX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -4.5%
1/23 Form 4 CHIMERIX INC For: Jan 21 Filed by: Jakeman David -4.0%
10/3 Form 8-K CHIMERIX INC For: Sep 30 -4.0%
7/31 Form D CHIMERIX INC -3.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: